Osimertinib-Induced Cardiomyopathy
Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-04-01
|
| Series: | JACC: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666084920300395 |
| _version_ | 1831592119205101568 |
|---|---|
| author | Shruti R. Patel, MD Sherry-Ann N. Brown, MD, PhD Jilan E. Kubusek, PharmD, RPh Aaron S. Mansfield, MD Narjust Duma, MD |
| author_facet | Shruti R. Patel, MD Sherry-Ann N. Brown, MD, PhD Jilan E. Kubusek, PharmD, RPh Aaron S. Mansfield, MD Narjust Duma, MD |
| author_sort | Shruti R. Patel, MD |
| collection | DOAJ |
| description | Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib is reversible and occurs at a dose of 80 mg/day. (Level of Difficulty: Intermediate.) |
| first_indexed | 2024-12-18T01:37:33Z |
| format | Article |
| id | doaj.art-6889c28d715f4f36b0342a1f711a1531 |
| institution | Directory Open Access Journal |
| issn | 2666-0849 |
| language | English |
| last_indexed | 2024-12-18T01:37:33Z |
| publishDate | 2020-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JACC: Case Reports |
| spelling | doaj.art-6889c28d715f4f36b0342a1f711a15312022-12-21T21:25:25ZengElsevierJACC: Case Reports2666-08492020-04-0124641645Osimertinib-Induced CardiomyopathyShruti R. Patel, MD0Sherry-Ann N. Brown, MD, PhD1Jilan E. Kubusek, PharmD, RPh2Aaron S. Mansfield, MD3Narjust Duma, MD4Department of Internal Medicine, Mayo Clinic, Rochester, MinnesotaDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MinnesotaDepartment of Medical Oncology, Mayo Clinic, Rochester, MinnesotaDepartment of Medical Oncology, Mayo Clinic, Rochester, MinnesotaDivision of Medical Oncology, University of Wisconsin, Madison, Wisconsin; Address for correspondence: Dr. Narjust Duma, University of Wisconsin, Division of Medical Oncology, 600 Highland Avenue, Madison, Wisconsin 53705.Osimertinib is the preferred treatment in patients with metastatic non–small cell lung cancer with epidermal growth factor receptor mutations. We report a case series of acute cardiomyopathy with heart failure exacerbation during osimertinib treatment. We suggest that cardiotoxicity from osimertinib is reversible and occurs at a dose of 80 mg/day. (Level of Difficulty: Intermediate.)http://www.sciencedirect.com/science/article/pii/S2666084920300395cardiotoxicitycardio-oncologyheart failureosimertinibreduced ejection fraction |
| spellingShingle | Shruti R. Patel, MD Sherry-Ann N. Brown, MD, PhD Jilan E. Kubusek, PharmD, RPh Aaron S. Mansfield, MD Narjust Duma, MD Osimertinib-Induced Cardiomyopathy JACC: Case Reports cardiotoxicity cardio-oncology heart failure osimertinib reduced ejection fraction |
| title | Osimertinib-Induced Cardiomyopathy |
| title_full | Osimertinib-Induced Cardiomyopathy |
| title_fullStr | Osimertinib-Induced Cardiomyopathy |
| title_full_unstemmed | Osimertinib-Induced Cardiomyopathy |
| title_short | Osimertinib-Induced Cardiomyopathy |
| title_sort | osimertinib induced cardiomyopathy |
| topic | cardiotoxicity cardio-oncology heart failure osimertinib reduced ejection fraction |
| url | http://www.sciencedirect.com/science/article/pii/S2666084920300395 |
| work_keys_str_mv | AT shrutirpatelmd osimertinibinducedcardiomyopathy AT sherryannnbrownmdphd osimertinibinducedcardiomyopathy AT jilanekubusekpharmdrph osimertinibinducedcardiomyopathy AT aaronsmansfieldmd osimertinibinducedcardiomyopathy AT narjustdumamd osimertinibinducedcardiomyopathy |